Trial Profile
A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 876 in Subjects With Type 2 Diabetes
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Efruxifermin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Amgen
- 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
- 08 Oct 2014 Planned End Date changed from 1 May 2015 to 1 Nov 2014 as reported by ClinicalTrials.gov
- 08 Oct 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov